Triana Biomedicines closed a $120 million Series B round led by Pfizer Ventures and other investors to advance its CCNK molecular glue degrader program into clinical studies. The financing will support proof‑of‑concept work and IND‑enabling activities for the lead degrader and related pipeline assets. Coverage emphasized Triana’s approach to targeted protein degradation and the investor backing from a major pharma as a signal of confidence in molecular glue modalities. Triana plans to use the funds to accelerate preclinical development and prepare for early clinical testing.